Kymera to Report KT-621 Eczema Data by Year-End
Kymera Therapeutics plans to announce mid-stage trial results for its eczema candidate KT-621 before the end of 2026.
Updated on Nov. 2, 2026 in Biotech
Massachusetts biotech Kymera Therapeutics plans to announce mid-stage clinical trial data for KT-621, its lead asset, in eczema before the end of 2026. The pill is being tested against eczema, a market served by Dupixent, a top-selling immunology drug.
Why it matters
Dupixent is used by 1.4 million patients for eczema, asthma, and chronic obstructive pulmonary disease, and a successful oral alternative could reshape treatment options for U.S. patients with the condition. Analysts have described the upcoming readout as one of the most impactful immunology and inflammation data releases this year.
The data consists of analyst sales projections and the existing patient base for Dupixent, the leading comparator drug. Trial efficacy results for KT-621 have not been disclosed and will not be known until Kymera's planned end-of-2026 announcement.
The players
Kymera Therapeutics
A Massachusetts biotechnology company developing KT-621 as its lead asset in immunology and inflammation.
Dupixent
A top-selling immunology drug used by 1.4 million patients for eczema, asthma, and chronic obstructive pulmonary disease.
The details
Kymera Therapeutics is developing KT-621 as a pill for eczema and is testing it in a mid-stage clinical trial. The company plans to share the trial data before the end of 2026, and Jefferies market analysts have called the results one of the most impactful immunology readouts this year.
Timeline
End of 2026: Kymera plans to announce KT-621 eczema trial data.
2035: Analysts project KT-621 sales could reach nearly $4 billion.
Market Landscape
KT-621 enters an eczema market led by Dupixent, a biologic that has set the standard for treatment in the category. Kymera's pill would challenge that incumbent with a non-injectable option if its mid-stage data hold up.
If KT-621 proves effective, eczema patients could have an oral option instead of injections, which may change how they manage flare-ups and daily treatment routines. Patients should discuss any new therapy with their dermatologist once results and approval status are available.
The takeaway
A pill-based eczema therapy would be a meaningful development for U.S. patients who currently rely on injectables such as Dupixent. Readers should watch for Kymera's end-of-2026 trial data to judge whether KT-621 can deliver on its projected market potential.
What happens next
Kymera plans to announce KT-621 mid-stage eczema trial data before the end of 2026.
Further reading
Explore more biotech developments shaping treatment options for chronic inflammatory conditions.
